Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: A retrospective bicenter study by the SFRO brachytherapy group.
Ka K, Schiappa R, Terlizzi M, Mallet F, Martin E, Chand ME, Demogeot N, Peiffert D, Pommier P, Quivrin M, Kissel M, Pasquier C, Khalifa J, Bossi A, Hannoun-Levi JM, Blanchard P.
Ka K, et al. Among authors: demogeot n.
Radiother Oncol. 2023 Mar;180:109460. doi: 10.1016/j.radonc.2022.109460. Epub 2023 Jan 10.
Radiother Oncol. 2023.
PMID: 36638842